Elan Corporation, plc (ELN)
-NYSE 12.35 
0.31(2.57%) 11:31AM EDT - Nasdaq Real Time Price
| Prev Close: | 12.04 |
|---|
| Open: | 12.16 |
|---|
| Bid: | 12.35 x 2900 |
|---|
| Ask: | 12.36 x 1200 |
|---|
| 1y Target Est: | 12.56 |
|---|
| Beta: | 1.25 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 12.15 - 12.42 |
|---|
| 52wk Range: | 9.37 - 14.91 |
|---|
| Volume: | 18,267,776 |
|---|
| Avg Vol (3m): | 6,421,500 |
|---|
| Market Cap: | 6.30B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.07 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Elan: Royalty Pharma reduces acceptance condition to 50% plus one shareBriefing.com(Thu 6:33AM EDT)
- Royalty Pharma Reduces Acceptance Condition to 50% Plus One SharePR Newswire(Thu 6:31AM EDT)
- Value Investor Seth Klarman's Shakeupsat Motley Fool(Wed, May 22)
- Alkermes Earnings Seen Rising, But Sales Uncertainat Investor's Business Daily(Wed, May 22)
- When Savvy Dealmaking Borders on Reckless Spendingat Motley Fool(Tue, May 21)
- Elan Provides Strategic UpdateZacks(Tue, May 21)
- Flush With Cash, Elan Goes on a Buying Spreeat Motley Fool(Tue, May 21)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue, May 21)
- Elan Proposes Sweeping Transformationat Motley Fool(Tue, May 21)
- Theravance pullback on Elan bid a buying opportunity, says Piper Jaffrayat theflyonthewall.com(Tue, May 21)
- Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trialsat Motley Fool(Mon, May 20)
- Royalty raises Elan bid, issues ultimatum to shareholdersat Reuters(Mon, May 20)
- Royalty ups Elan bid and issues shareholder ultimatumat Reuters(Mon, May 20)
- Royalty Pharma Raises Bid for a Resistant Elanat New York Times(Mon, May 20)
- Elan’s Response to Royalty Pharma AnnouncementBusiness Wire(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 61.77 |
|---|
| P/S (ttm): | 30,703.99 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 75.26 |
|---|
Business Summary
Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ...
View More